National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.

Autor: Cristofaro, JV, Ansher, SS, Zwiebel, JA, Ivy, P, Conley, B, Abrams, JS, Doroshow, JH

Publikováno v: Clinical Pharmacology & Therapeutics; May2017, Vol. 101 Issue 5, p616-618, 3p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

Autor: Abrams JS; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20852, USA. abramsj@mail.nih.gov, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2013 Jul 03; Vol. 105 (13), pp. 954-9. Date of Electronic Publication: 2013 Jun 17.

The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development.

Autor: Ansher SS; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA. anshers@ctep.nci.nih.gov, Scharf R

Publikováno v: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2001 Dec; Vol. 949, pp. 333-40.

Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity.

Autor: Ansher SS, Dolan P, Bueding E

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 1983 Nov-Dec; Vol. 3 (6), pp. 932-5.